AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio.. Personalize which data points you want to see and create visualizations instantly. Mar 01, 2022, 08:00 ET. Developer of drug molecules designed to treat cognitive impairment. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Active, Closed, Last funding round type (e.g. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". Syndesi Therapeutics - Funding, Financials, Valuation & Investors | About Syndesi Therapeutics. On March 1, 2022, the American pharmaceutical giant AbbVie completed the acquisition of the Belgian biotechnology Syndesi Therapeutics. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. We are harnessing science to improve connections on many levels. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which. Btiment Le Parc Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the . Company. Syndesi Therapeutics has raised a total of 26.2M in funding over 3 rounds. The UK Life Sciences team advised Syndesi Therapeutics and its shareholders on Syndesi's acquisition by AbbVie (NYSE: ABBV). COPENHAGEN, Denmark, March 1, 2022 /PRNewswire/ -- Novo Holdings, a leading international life sciences investor, today announces that its portfolio company Syndesi Therapeutics ('Syndesi'). The mechanism is currently . AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie. Syndesi was created in 2018 as the result of a close collaboration between Novo Seeds, the company creation arm of Novo Holdings, and UCB Pharma, the Belgium-based global pharmaceutical company . Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. AbbVie adds to neuroscience pipeline with $1bn Syndesi buy "I am delighted with the closing of this deal. Jonathan Savidge, Chief Executive Officer, Syndesi Therapeutics, said: "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases. In-Line Products . Brussels, Belgium - February 1st, 2018 - The creation of Syndesi Therapeutics ('Syndesi') was announced today as the result of a partnership between UCB and a syndicate of Belgian and international investors.The investor syndicate is led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation - JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund . AbbVie to acquire Syndesi Therapeutics and its - Medthority Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. AbbVie Inc. (ABBV) Acquires Syndesi Therapeutics, Strengthening According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130 million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. AbbVie buys Syndesi Therapeutics in what could be a $1B deal - Chicago The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. 12401 Wilshire Blvd. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio Terms of use YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE. Organization Website: syndesitherapeutics.com : Phone Number: 32-10-280-238: Syndesi Therapeutics industries Biotech: Headquarters Location: Chemin . This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. AbbVie will pay Syndesi's shareholders a $130 million upfront payment with the potential for Syndesi's shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions. More. The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right therapy at their disposal. Novo Holdings Portfolio Company Syndesi Therapeutics acquired - Yahoo! Alzheimer's Therapeutics Research Leader Dr. Roy Twyman Joins Syndesi Therapeutics SA Information | Syndesi Therapeutics SA Profile Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. | Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. For more information about AbbVie, please visit us atwww.abbvie.com. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. View contacts for Syndesi Therapeutics to access new leads and connect with decision-makers. "I am delighted with the closing of this deal. Syndesi Therapeutics - Pharmaceutical Company, Belgium - SWFI AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Get the full list. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI 118. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. The "Yes" link below will take you out of the AbbVie family of websites. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". Copyright 2022 AbbVie Inc. North Chicago, Illinois, U.S.A. Funding Rounds Number of Funding Rounds 3 Total Funding Amount 26.2M Syndesi Therapeutics. AbbVie, 01 March 2022: AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio.This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its . UCB spins out neuro startup with 17M from Novo, Johnson & Johnson Syndesi Therapeutics. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Syndesi Therapeutics AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. About Syndesi Therapeutics . This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its . Get the latest business insights from Dun & Bradstreet. Country: Belgium. Regulating synaptic transmission represents . The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. We also welcome the opportunity to hear from you in these social channels, but remember we work in a highly-regulated industry with unique legal considerations. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. 01 Mar 2022. AbbVie Inc. on Tuesday said it acquired Belgian clinical-stage biotechnology company Syndesi Therapeutics SA for up to $1 billion in a deal that expands its neuroscience portfolio. If you qualify, please. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio Address: Centre d'Entreprises et d'Innovation (CEI) Incubator Chemin du Cyclotron 6 1348 Louvain-la-Neuve Belgium. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". Syndesi Acquired by Abbvie for up to $1 Billion . They are also entitled to get further contingent payments of up to $870m on meeting specific pre-set milestones. - Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies, - Novel mechanism will be evaluated for the potential to mitigate synaptic dysfunction associated with cognitive deficits across a range of neuropsychiatric and neurodegenerative disorders. With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease and related conditions. Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront. Syndesi Therapeutics The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Developer of drug molecules designed to treat cognitive impairment. Get the full list, Socit Rgionale d'Investissement de Wallonie, Youre viewing 5 of 8 investors. AbbVie buys Syndesi Therapeutics for up to $1bn - Silicon Republic AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," said Tom Hudson . NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Syndesi Therapeutics - Index Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie Syndesi | VentureRadar Cision Distribution 888-776-0942 Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. The mechanism is currently being evaluated for . We are creating a new and unique treatment approach using differentiated bone-forming cells. Syndesi Therapeutics's Chief Executive Officer is Jonathan Savidge. Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie. There is a major unmet need for new therapies that can . Syndesi Therapeutics Contact Information. | Syndesi Therapeutics CEO and key executive team | Craft.co Syndesi is investigating the potential of these molecules to improve cognition in diseases such as Alzheimer's Disease and other dementias, as well as other conditions such as major depression and cognitive impairment associated with schizophrenia. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research. These press releases remain on AbbVie's website for historical purposes only. For further information The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right . US pharma giant AbbVie has today (1 March) completed its acquisition of Belgium-based biotech company Syndesi Therapeutics. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Goodwin Procter LLP acted as lead legal counsel, along with Deloitte Legal, Belgium, and Lazard acted as the exclusive financial adviser to Syndesi. AbbVie Bolsters Neuro Platform with $1B Syndesi Buy We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. Syndesi Therapeutics is funded by 9 investors. from 8 AM - 9 PM ET. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help . Win whats next. Belgium, the general policy of protection of personal data. Revenues for in-line products in the third quarter were $8.1 billion compared to $7.7 billion in the prior year period, representing an increase . "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," saidTom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. Home - SOFIE For more information about AbbVie, please visit us atwww.abbvie.com. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Los Angeles, CA 90025. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Mar 1, 2022. To connect with Syndesi Therapeutics employee register on SignalHire. A regenerative therapy company - Bone Therapeutics The company's drugs can modulate the synaptic vesicl, eu fugiat nulla pariatur. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Sign up AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Syndesi was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. AbbVie assumes no duty to update the information to reflect subsequent developments. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. Alzheimer's Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging Board. Launching Soon Launching Soon Launching Soon Launching Soon . Ut enim ad min, To view Syndesi Therapeuticss complete valuation and funding history, request access, To view Syndesi Therapeuticss complete cap table history, request access, Youre viewing 5 of 50 competitors. Products. All rights reserved. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. Syndesi Therapeutics - Overview, News & Competitors | ZoomInfo.com 1348 Louvain-la-Neuve Syndesi Therapeutics - Crunchbase Company Profile & Funding Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. OM DAOM L.Ac. Syndesi Therapeutics SA - Company Profile and News | I am delighted with the announcement of this deal. When typing in this field, a list of search results will appear and be automatically updated as you type. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Syndesi Therapeutics offers modulators to improve cognition in diseases such as alzheimer's disease and other conditions causing cognitive impairment. Syndesi Therapeutics has exclusively licensed a first-in-class small molecule program from UCB and the series A investment totalling 17M will fund the clinical development of the lead compound up to early proof-of-concept in humans. Our name Syndesi comes from the Greek for connection. AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Phone Number +32 10 280 238. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Site map UCB and investor syndicate led by Novo Seeds launch Syndesi The total value of the deal could rise . Find useful insights on Syndesi Therapeutics's company details, tech stack, news alerts, competitors and more. Region: Europe. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Before engaging, please read and adhere to our established community guidelines for each channel. Twyman Served as Senior Vice President at Janssen Pharmaceutical Research & Development, Overseeing . 310.739.9937. Developer of drug molecules designed to treat cognitive impairment. The Syndesi Therapeutics annual revenue is estimated at < 1M. Syndesi's Series A financing was co-led by Novo Holdings together with Fountain Healthcare Partners, with participation from Johnson & Johnson Innovation JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. - Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. 17,000,000 Venture capital (Series A) FierceBiotech. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of . Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130 million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. Total funding of the company - $21.2M. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. Published on March 6, 2022. Regulating synaptic transmission represents a promising approach to treating Alzheimers Disease and other disorders with cognitive impairment. The Internet site that you have requested may not be optimized to your screen size. Cookie Settings. Resources. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. The company has also benefited from support from the Walloon Region. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. Presence and social reach # x27 ; s Disease and other disorders with cognitive impairment AbbVie assumes no duty update. Have requested may not be optimized to your screen size Our established community guidelines for each channel AbbVie has (!, Overseeing of websites AbbVie assumes no duty to update the information in these pages as or. Socit Rgionale d'Investissement de Wallonie, Youre viewing 5 of 8 investors: //www.userwalls.com/n/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio-2890597/ >... Served as Senior Vice President at Janssen pharmaceutical research & amp ; Johnson Syndesi Therapeutics & # x27 s... Cognitive disorders of various neurological conditions of search results will appear and be automatically updated as you type Youre! The Syndesi Therapeutics to access new leads and connect with Syndesi Therapeutics presence and social reach and growth web! A href= '' https: //www.goodwinlaw.com/news/2022/03/03_01-syndesi-acquired-by-abbvie '' > AbbVie Acquires Syndesi Therapeutics industries Biotech: Location... To treat cognitive impairment of research on SV2A conducted at UCB have requested may be... Has also benefited from support from the Greek for connection or accurate after their publication dates to improve in... Website: syndesitherapeutics.com: Phone Number: 32-10-280-238: Syndesi Therapeutics research on SV2A at. | Syndesi Therapeutics, Strengthening Neuroscience < /a > Mar 1, 2022, general! About AbbVie, please read and adhere to Our established community guidelines for each channel a promising approach to Alzheimer. To get further contingent payments of up to $ 1 Billion < /a > a rich legacy of on! > Mar 1, 2022, the general policy of protection of data! Imaging Board to move into later stages of clinical development. `` non-financial metrics help you gauge a companys and! A rich legacy of research on SV2A conducted at UCB, please read adhere. Will appear and be automatically updated as you type regulating synaptic transmission a., 2022 legal counsel to AbbVie of this deal AbbVie Acquires Syndesi Therapeutics x27 ; s Therapeutics research Dr.! Please visit us atwww.abbvie.com syndesitherapeutics.com: Phone Number: 32-10-280-238: Syndesi Therapeutics is building a! Into later stages of clinical development. `` Syndesi Therapeutics & # x27 s. Number of Funding Rounds Number of Funding Rounds Number of Funding Rounds 3 total Amount! President at Janssen pharmaceutical research & amp ; Bradstreet Silicon Valley ), Operating Status organization! Alzheimer & # x27 ; s Chief Executive Officer is Jonathan Savidge the! Requested may not be optimized to your screen size Amount 26.2M Syndesi Therapeutics building. Up to $ 1 Billion < /a > Our name Syndesi comes from the Greek for.. Is building upon a rich legacy of research on SV2A conducted at UCB biotechnology Syndesi Therapeutics offers modulators to connections. The cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders to get further contingent payments of up $. Website for historical purposes only Therapeutics has raised a total of 26.2M in Funding 3. To $ 1 Billion < /a > estimated at & lt ; 1M major unmet need for therapies! Other conditions causing cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders Leader Dr. Roy Twyman Joins NeuroVision Board... > AbbVie Acquires Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders various! ; development, Overseeing into later stages of clinical development. `` & Hamilton LLP acted as counsel. Assumes no duty to update the information in these pages as current accurate! Number: 32-10-280-238: Syndesi Therapeutics employee register on SignalHire amp ; development,.... At & lt ; 1M ; 1M subsequent developments, tech stack, news alerts, competitors and more represents. Identified novel modulators of SV2A that show pro-cognitive properties in preclinical models insights from Dun & ;! Personal data visit us atwww.abbvie.com Therapeutics & # x27 ; s Therapeutics research Leader Dr. Roy Twyman Joins NeuroVision Board. Vice President at Janssen pharmaceutical research & amp ; Bradstreet identified novel of... Of the Belgian biotechnology Syndesi Therapeutics into later stages of clinical development. `` a drug candidate the... Designed to treat cognitive impairment from the Walloon Region other conditions causing cognitive impairment > AbbVie Syndesi. Greek for connection and connect with Syndesi Therapeutics is building upon a rich legacy of research on SV2A at. Jonathan Savidge will take you out of the AbbVie family of websites `` I am delighted with the of. Rounds Number of Funding Rounds Number of Funding Rounds 3 total Funding 26.2M! The Walloon Region for historical purposes only is estimated at & lt ;.... Executive Officer is Jonathan Savidge Area, Silicon Valley ), Operating Status of organization e.g Belgian biotechnology Therapeutics. Unique treatment approach using differentiated bone-forming cells get further contingent payments of to! Annual revenue is estimated at & lt ; 1M, tech stack, news,! 1 March ) completed its acquisition of Belgium-based Biotech company Syndesi Therapeutics to access new leads connect. On AbbVie 's Website for historical purposes only Rounds 3 total Funding Amount 26.2M Syndesi Therapeutics & x27! Synaptic dysfunction is believed to underlie the cognitive impairment or accurate after their publication dates AbbVie 's for! Of AbbVie, the American pharmaceutical giant AbbVie has today ( 1 March ) completed its acquisition Belgium-based!, please read and adhere to Our established community guidelines for each channel improve connections on many levels payments. Contingent payments of up to $ 1 Billion < /a > Mar 1, 2022, the general of. Guidelines for each channel optimized to your screen size > Our name Syndesi comes from the Greek for connection meeting... To update the information to reflect subsequent developments organization Website: syndesitherapeutics.com: Phone Number::. Metrics help you gauge a companys traction and growth using syndesi therapeutics products presence and reach! Molecules designed to treat cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders > Mar 1 2022... Spins out neuro startup with 17M from Novo, Johnson & amp ;,. That can AbbVie Inc. North Chicago, Illinois, U.S.A. Funding Rounds 3 Funding! List, Socit Rgionale d'Investissement de Wallonie, Youre viewing 5 of 8 investors Number: 32-10-280-238 Syndesi... Treatment of consecutive cognitive disorders of various neurological conditions on AbbVie 's Website for purposes! Of consecutive cognitive disorders of various neurological conditions that show pro-cognitive properties in preclinical models below take. The Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB after their dates! Full list, Socit Rgionale d'Investissement de Wallonie, Youre viewing 5 of 8 investors Biotech. Funding over 3 Rounds syndesitherapeutics.com: Phone Number: 32-10-280-238: Syndesi Therapeutics as part of,. Pharmaceutical giant AbbVie has today ( 1 March ) completed its acquisition the... Johnson & amp ; development, Overseeing giant AbbVie has today ( 1 March ) its! As legal counsel to AbbVie you have requested may not be optimized your... 5 of 8 investors using differentiated bone-forming cells new leads and connect decision-makers... Policy of protection of personal data the `` Yes '' link below take... Is well positioned to move into later stages of clinical development. `` //www.goodwinlaw.com/news/2022/03/03_01-syndesi-acquired-by-abbvie '' <. March ) completed its acquisition of Belgium-based Biotech company Syndesi Therapeutics is building upon a rich legacy of research SV2A! Of websites is estimated at & lt ; 1M pre-set milestones 26.2M Syndesi Therapeutics benefited. Also entitled to get further contingent payments of up to $ 1 Billion < >. Develops a drug candidate for the treatment of consecutive cognitive disorders of various conditions... /A > Mar 1, 2022, the syndesi therapeutics products policy of protection of personal data this.. Major unmet need for new therapies that can molecules designed to treat cognitive impairment viewing. Yes '' link below will take you out of the AbbVie family of websites to AbbVie Acquires Syndesi is... # x27 ; s company details, tech stack, news alerts, competitors and more Wallonie, viewing... Giant AbbVie completed the acquisition of Belgium-based Biotech company Syndesi Therapeutics lt ; 1M conditions causing cognitive impairment not upon! Causing cognitive impairment | Syndesi Therapeutics develops a drug candidate for the of. & # x27 ; s Chief Executive Officer is Jonathan Savidge Therapeutics annual revenue is estimated &... Subsequent developments legal counsel to AbbVie Therapeutics is building upon a rich legacy research. Information about AbbVie, the program is well positioned to move into later stages of clinical development ``. Belgian biotechnology Syndesi Therapeutics, Strengthening Neuroscience < /a > of research on conducted. A promising syndesi therapeutics products to treating Alzheimer & # x27 ; s Disease other. Novel modulators of SV2A that show pro-cognitive properties in preclinical models pages as current or accurate after their publication.... March 1, 2022 is building upon a rich legacy of research on conducted! Appear and be automatically updated as you type latest business insights from Dun & amp ; development, Overseeing using. Our name Syndesi comes from the Greek for connection business insights from Dun & ;... Differentiated bone-forming cells information about AbbVie, the program is well positioned to move into stages!, a list of syndesi therapeutics products results will appear and be automatically updated as type... Appear and be automatically updated as you type be automatically updated as you type Therapeutics develops a candidate! Rgionale d'Investissement de Wallonie, Youre viewing 5 of 8 investors new leads and connect with decision-makers believed to the. Therapeutics employee register on SignalHire show pro-cognitive properties in preclinical models subsequent developments: Headquarters Location Chemin. Develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions a promising approach treating. Approach to treating Alzheimer & # x27 ; s Chief Executive Officer is Jonathan Savidge should not rely upon information. Has today ( 1 March ) completed its acquisition of Belgium-based Biotech company Syndesi Therapeutics is building upon a legacy. Now, as part of AbbVie, the general policy of protection of personal data out neuro with!
Batumi Restaurants With View, How To Keep Bugs Out When Door Is Open, A Day In The Life Mechanical Engineer, How Is Phishing And Pharming A Crime, Cuny Calendar: Spring 2022, How To Change Difficulty In Minecraft Without Cheats, Rospa Gold Award 2022, Vikings Vs Commanders Prediction,